Autonomix Medical, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Autonomix Medical (NASDAQ: AMIX), a medical device company specializing in nervous system disease diagnostics and treatment technologies, has announced an inducement stock option grant. The Compensation Committee approved on March 17, 2025, options to purchase 7,500 shares of common stock for a new non-executive employee.
The stock options, granted under Nasdaq Rule 5635(c)(4), have a ten-year term and will vest in four equal annual installments. The exercise price matches the closing price of Autonomix's common stock on the Nasdaq Capital Market as of March 17, 2025. The grant serves as part of the employee's compensation package and was provided as an inducement for their employment.
Positive
- None.
Negative
- None.
THE WOODLANDS, TX, March 21, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that the Compensation Committee of Autonomix’s Board of Directors approved the grant of an inducement stock option on March 17, 2025 to purchase 7,500 shares of the Company’s common stock, to a new non-executive employee pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception, as a component of the individual’s employment compensation and was granted as an inducement material to their start of employment with the Company.
The option has an exercise price equal to the closing price of Autonomix’s common stock as reported by the Nasdaq Capital Market on March 17, 2025. The options have a ten-year term and vest in four equal annual installments, subject to the employee’s continued services to the Company through the applicable vesting dates.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Forward Looking Statements
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the potential of the technology to treat cancerous tumors and the pain associated with pancreatic cancer, to submit and receive approval of an IDE, and to file a De Novo application. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.”
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 31, 2024, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com
FAQ
What are the vesting terms for AMIX's March 2025 inducement stock options?
How many shares were included in AMIX's March 2025 inducement grant?
What is the exercise price for AMIX's March 2025 inducement options?
Under which Nasdaq rule was AMIX's March 2025 stock option grant issued?
